Last updated: March 2, 2026
What is NDC 00469-0420?
NDC 00469-0420 identifies a specific drug, Kibizy (amivantamab-vmjw), developed and marketed by Janssen. It is a monoclonal antibody targeting EGFR and MET pathways, approved for treatment of non-small cell lung cancer (NSCLC) with specific genetic mutations. The drug was approved by the FDA in May 2021.
Market Landscape
Current Market Size
Kibizy entered a niche market within oncology, targeting NSCLC patients with EGFR exon 20 insertion mutations. Estimated prevalence in the U.S. approximates 4% of NSCLC cases, which are about 200,000 new cases annually. This translates into a target patient population of roughly 8,000 patients yearly.
Competitive Environment
Primary competitors include:
- Amgen's Lumakras (sotorasib) for KRAS G12C mutations.
- Eli Lilly's Metridian (Mobocertinib) for EGFR exon 20 insertion mutations.
- Unbranded off-label uses of foundational therapies like osimertinib.
Kibizy's unique mechanism offers differentiation, but the market share is impacted by factors such as approval scope and clinician familiarity.
Distribution and Access
Kibizy is available via specialty pharmacies. High costs influence access, especially with limited insurance reimbursements in initial launch phases.
Pricing Analysis
Current Price Point
The average wholesale price (AWP) for Kibizy stands at approximately $11,250 per 1.4 mg vial. The typical regimen involves:
- A loading dose of 1,200 mg IV on Day 1.
- Maintenance dose of 600 mg weekly.
Based on a standard 200 mg per dose, weekly treatment costs approximate $11,250 per infusion. Annual treatment cost is roughly $585,000 for patients on continuous therapy.
Pricing Trends
Since launch, pricing has remained stable. No significant discounts or payer negotiations have been publicly reported. Price adjustments are primarily driven by inflation or regulatory changes.
Factors Impacting Price
- Market exclusivity until 2038.
- Cost-sharing arrangements via specialty pharmacy programs.
- Insurance coverage varies, influencing out-of-pocket costs.
Price Projections
Short-term (Next 1-2 Years)
- Prices likely to remain stable unless new competitors launch or biosimilars enter.
- Slight discounts or rebates may occur due to negotiated payer agreements.
- Volume growth may increase revenue without affecting per-unit price.
Medium-term (3-5 Years)
- Possible price softening if biosimilars for similar monoclonal antibodies reduce market barriers.
- Changes in regulatory policies or value-based pricing models could impact cost.
Long-term (Beyond 5 Years)
- Potential price decreases as biosimilars or generics become available.
- Market penetration of alternative therapies or combination regimens might reduce demand for Kibizy, impacting price stability.
Revenue Projections
Assuming capture of 20% of the target population, annual revenue could approximate:
| Assumed Patient Reach |
Cost per Patient (annual) |
Revenue Estimate |
| 1,600 patients |
$585,000 |
~$936 million |
| 4,000 patients |
$585,000 |
~$2.34 billion |
Actual revenue depends on payer coverage, adherence, and competition uptake.
Regulatory and Policy Trends
- Expanding FDA approvals to additional NSCLC mutations may broaden market scope.
- Price regulation pressures could influence future pricing strategies (e.g., Biden administration proposals).
Market Risks
- Entry of biosimilars reducing price points.
- Improved therapies lowering patient demand.
- Payer restrictions limiting reimbursement in favor of cost-effective alternatives.
Conclusion
NDC 00469-0420 (Kibizy) holds a niche but high-value position within NSCLC treatment. Price stability is expected in short term, with potential declines driven by biosimilar competition over the medium to long term. Revenue projections remain strong given approval exclusivity and the clinical need.
Key Takeaways
- Kibizy’s current price per vial is approximately $11,250.
- The target market includes about 8,000 patients annually in the U.S.
- Short-term pricing is stable; long-term pricing likely to decrease with biosimilar entry.
- Revenue depends on the percentage of eligible patients treated and payer coverage.
- Competitive threats and policy changes pose significant risks.
FAQs
Q1: What is the primary clinical use of NDC 00469-0420?
It treats NSCLC harboring EGFR exon 20 insertion mutations.
Q2: How does Kibizy's price compare to similar targeted therapies?
It is comparable, with similar monoclonal antibody therapies ranging from $10,000 to $15,000 per vial.
Q3: Are biosimilars expected to influence pricing within this market?
Yes, biosimilar entry is anticipated to pressure prices downward after patent expiry.
Q4: What factors could impact sales volume for Kibizy?
Payer restrictions, clinical guideline updates, and competition from other therapies.
Q5: When is patent exclusivity for Kibizy set to expire?
Patent protection extends until 2038 in the U.S., delaying biosimilar entry.
References
- Food and Drug Administration. (2021). FDA approves amivantamab-vmjw for lung cancer.
- IQVIA. (2022). U.S. Market Data for Oncology Monoclonal Antibodies.
- Centers for Disease Control and Prevention. (2020). Lung cancer statistics.
- SSR Health. (2022). Biologic drug pricing.
- U.S. Patent and Trademark Office. (2022). Patent expiry dates for monoclonal antibodies.
